vTv Therapeutics Management
Management criteria checks 1/4
vTv Therapeutics' CEO is Paul Sekhri, appointed in Aug 2022, has a tenure of 2.75 years. total yearly compensation is $3.86M, comprised of 16.1% salary and 83.9% bonuses, including company stock and options. directly owns 0.19% of the company’s shares, worth €115.01K. The average tenure of the management team and the board of directors is 2.3 years and 1.3 years respectively.
Key information
Paul Sekhri
Chief executive officer
US$3.9m
Total compensation
| CEO salary percentage | 16.09% |
| CEO tenure | 2.8yrs |
| CEO ownership | 0.2% |
| Management average tenure | 2.3yrs |
| Board average tenure | 1.3yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2025 | n/a | n/a | -US$19m |
| Dec 31 2024 | US$4m | US$622k | -US$18m |
| Sep 30 2024 | n/a | n/a | -US$18m |
| Jun 30 2024 | n/a | n/a | -US$20m |
| Mar 31 2024 | n/a | n/a | -US$21m |
| Dec 31 2023 | US$1m | US$480k | -US$20m |
| Sep 30 2023 | n/a | n/a | -US$22m |
| Jun 30 2023 | n/a | n/a | -US$19m |
| Mar 31 2023 | n/a | n/a | -US$17m |
| Dec 31 2022 | US$2m | US$200k | -US$19m |
Compensation vs Market: Paul's total compensation ($USD3.86M) is above average for companies of similar size in the German market ($USD493.58K).
Compensation vs Earnings: Paul's compensation has increased whilst the company is unprofitable.
CEO
Paul Sekhri (66 yo)
Mr. Paul J. Sekhri, M.Sc. served as Director of Quercis Pharma AG until 2025. Mr. Sekhri is Director at AdhereTech Inc. since February 7, 2024. He serves as Chief Executive Officer, President & Director of...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Chairman of the Board | 2.8yrs | US$3.86m | 0.19% € 115.0k | |
| Executive VP & CFO | no data | no data | no data | |
| Chief Accounting Officer | 3.2yrs | US$434.75k | 0.00015% € 90.1 | |
| Chief Scientific Officer & Executive VP | no data | no data | no data | |
| Executive VP & General Counsel | 2.3yrs | no data | no data | |
| Executive VP of Corporate Development & Director | 2.8yrs | US$547.40k | 0.057% € 34.5k | |
| Chief Medical Officer | 1.5yrs | no data | no data | |
| Chief Commercial Officer | less than a year | no data | no data |
Experienced Management: 5VT0's management team is considered experienced (2.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Chairman of the Board | 2.8yrs | US$3.86m | 0.19% € 115.0k | |
| Executive VP of Corporate Development & Director | 4.5yrs | US$547.40k | 0.057% € 34.5k | |
| Independent Director | less than a year | US$121.08k | 0.070% € 42.2k | |
| Independent Director | 1.3yrs | US$141.52k | 0.086% € 51.8k | |
| Independent Director | 1.3yrs | US$142.10k | 0.082% € 49.4k | |
| Lead Independent Director | 1.3yrs | US$153.34k | 0.070% € 42.2k | |
| Independent Director | 2.8yrs | US$142.09k | 0.16% € 96.4k |
Experienced Board: 5VT0's board of directors are not considered experienced ( 1.3 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/20 20:01 |
| End of Day Share Price | 2025/05/20 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
vTv Therapeutics Inc. is covered by 9 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| James Molloy | Alliance Global Partners |
| Corey Davis | Canaccord Genuity |
| Emily Bodnar | H.C. Wainwright & Co. |